|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/28/2008 9:22:45 AM
TOKYO--(BUSINESS WIRE)--Eisai Co., Ltd. (Tokyo, TSE 4523) (“Eisai”), a research-based human health care (hhc) company, today announced the completion of the offer by its indirect wholly-owned subsidiary, Jaguar Acquisition Corp. (“Jaguar”), to purchase all outstanding shares of the common stock of MGI PHARMA, INC. (NASDAQ: MOGN) (“MGI PHARMA”), including the associated preferred share purchase rights, for US$41.00 per share, without interest and subject to applicable withholding of taxes. As of 12:00 midnight (New York City time) on Friday, January 25, 2008, the expiration date of the previously announced subsequent offering period for the offer, 76,494,076 MGI PHARMA shares have been validly tendered into the offer, representing over 93.8% of the outstanding shares of MGI PHARMA. All shares validly tendered in the offer have been accepted for payment, and the consideration for all such shares either has been paid or will promptly be paid.
|
|
|
|
|
|
|
|
|
|
|